Daito Pharmaceutical Co.,Ltd.
Stock Price Chart
2026/09/21 UpdatedPrice Trend
2026/09/21 UpdatedPrice & Trading Details
2026/09/21 UpdatedPRICE
TRADING
Analyst Recommendations 1 analysts
Updated 2026/09/01Shareholder Composition
Updated 2026/09/01Major Holders
Updated 2026/09/01| Institution | Ownership | Shares | Change |
|---|---|---|---|
|
VANGUARD STAR FUNDS-Vanguard Total International Stock Index Fund
|
373.4K | 0.00% | |
|
DFA INVESTMENT DIMENSIONS GROUP INC-DFA Intl Small Cap Value PORT.
|
248.2K | 0.00% | |
|
VANGUARD TAX-MANAGED FUNDS-Vanguard Developed Markets Index Fund
|
217.8K | 0.00% | |
|
American Century ETF Trust-Avantis International Small Cap Value ETF
|
188.9K | +22.42% | |
|
DFA INVESTMENT TRUST CO-The Japanese Small Company Series
|
154.8K | +4.74% | |
|
Dimensional ETF Trust-Dimensional International Small Cap Value ETF
|
151.2K | +9.89% |
Dividend History
Updated 2026/09/20| Year | Dividend | Change |
|---|---|---|
| 2026 | ¥20 | -46.7% |
| 2025 | ¥38 | +15.4% |
| 2024 | ¥33 | +13.5% |
| 2023 | ¥29 | -3.1% |
| 2022 | ¥30 | - |
Financial Performance
2026/09/20 UpdatedRevenue & Profit
Margins
Cash Flow
Financial Health
| 2023 | 2024 | 2025 | 2026 | |
|---|---|---|---|---|
| Income Statement | ||||
| Revenue | ¥45,101M | ¥46,895M | ¥50,643M | ¥50,650M |
| Gross Profit | ¥10,331M | ¥9,839M | ¥8,637M | ¥9,897M |
| Operating Income | ¥5,208M | ¥3,894M | ¥2,620M | ¥3,637M |
| Pretax Income | ¥5,088M | ¥4,259M | ¥3,081M | ¥4,195M |
| Net Income | ¥3,600M | ¥3,295M | ¥1,908M | ¥3,161M |
| EPS | ¥113.71 | ¥105.00 | ¥62.74 | ¥107.49 |
| Operating Margin | 11.55% | 8.30% | 5.17% | 7.18% |
| Balance Sheet | ||||
| Total Assets | ¥70,552M | ¥77,708M | ¥78,004M | ¥73,291M |
| Total Equity | ¥50,672M | ¥52,068M | ¥52,003M | ¥52,891M |
| Total Liabilities | ¥19,880M | ¥25,640M | ¥26,001M | ¥20,400M |
| Cash | ¥3,607M | ¥2,727M | ¥2,207M | ¥954M |
| Interest-bearing Debt | ¥4,889M | ¥8,719M | ¥11,885M | ¥9,294M |
| Equity Ratio | 71.82% | 67.00% | 66.67% | 72.17% |
| D/E Ratio | 0.10 | 0.17 | 0.23 | 0.18 |
| Cash Flow | ||||
| Operating CF | ¥4,155M | ¥5,182M | ¥5,897M | ¥9,377M |
| Investing CF | -¥5,566M | -¥5,930M | -¥7,365M | -¥4,388M |
| Financing CF | ¥616M | -¥183M | ¥1,002M | -¥6,289M |
| Free CF | -¥1,401M | -¥1,094M | -¥1,198M | ¥4,160M |
| Efficiency | ||||
| ROE | 7.10% | 6.33% | 3.67% | 5.98% |
| ROA | 5.10% | 4.24% | 2.45% | 4.31% |
Latest IR Information
-
Financial Results Explanation Document
For the fiscal year ending May 2026, consolidated sales are forecasted to be 50,650 million yen (YoY +0.0%), with operating income at 3,637 million yen (up 38.8%). Increased research and development expenses and capital investments are expected to improve profit...
Read more -
Notice of Completion of Share Buyback｜July 2026
Diet Stock Corporation completed its share buyback implemented on July 10, 2026, acquiring 484,000 shares for a total of 600 million yen. This is part of its capital policy aimed at shareholder returns and enhancing capital efficiency.
Read more -
Financial Summary “Japan GAAP” (Consolidated) For the Fiscal Year Ended May 2026
Discloses full-year figures such as net sales. For the consolidated results for the fiscal year ending May 2026, YoY comparisons for revenue and profit items are provided, as well as major items from the balance sheet and income statement, and...
Read more -
Notice of Change of Representative Director, Appointment of New Director Candidates, and Change of Executive Officers
Announcement of the appointment of three new director candidates and changes to directors and executive officers. Resignation of the representative director with a view to becoming chairman, new appointments and transfers of executive officers, and the establishment of a new...
Read more -
Notice Regarding Share Buyback and Share Buyback Through off-auction ToSTNeT-3
As part of the medium-term management plan's capital policy, a share buyback will be conducted. The plan is to acquire 500,000 ordinary shares (upper limit) with a total upper limit of 625,000,000 yen, with the ToSTNeT-3 buy order scheduled for...
Read more
Latest News (5 items)
-
Average Analyst Rating: none
Average Target Price: ¥1,400
Rating Score: - (Based on 1 analysts)
※1=Strong Buy, 5=Strong Sell
North America Pharmaceutical Contract Packaging Market Size, 2034 - marketdataforecast.com ↗
Company Information
About
Daito Pharmaceutical Co.,Ltd. engages in the manufacture and sale of pharmaceutical products in Japan and internationally. It offers active pharmaceutical ingredients for generic drugs; develops and manufactures generic and over-the-counter drugs; and contract manufacturing services for ethical drugs. The company is also involved in the wholesale of pharmaceutical and veterinary medicine. It exports its products to the United States, as well as European and Asian countries. The company was formerly known as Daito Corporation and changed its name to Daito Pharmaceutical Co.,Ltd. in 1992. Daito Pharmaceutical Co.,Ltd. was incorporated in 1942 and is headquartered in Toyama, Japan.
